XOMA

76 articles with XOMA

• XOMA Declares Quarterly Preferred Stock Dividends - March 21, 2023

  3/21/2023

  XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization Strategy

  3/9/2023

  XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, reported its full year 2022 financial results and provided an operational update on the Company’s actions to accelerate XOMA’s differentiated biotech royalty and milestone acquisition strategy.

• XOMA to Present at 43rd Annual Cowen Health Care Conference

  2/28/2023

  XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will be featured in a fireside chat at the 43rd Annual Cowen Health Care Conference on Tuesday, March 7, 2023, at 2:10 PM ET.

• XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 07, 2023

  1/7/2023

  XOMA Corporation, the Biotech Royalty Aggregator, announced the Company has granted Owen Hughes, the Company’s newly appointed Executive Chairman, two separate non-qualified stock options to purchase: 100,000 shares of the Company’s common stock at an exercise price of $18.66 per share and 75,000 shares of the Company’s common stock at an exercise price of $30.00 per share on January 3, 2023.

• New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy

  1/4/2023

  XOMA Corporation, the Biotech Royalty Aggregator, announced Jim Neal has retired as Chief Executive Officer and two finance and biotechnology industry veterans have joined in newly created executive leadership roles to drive the Company’s next phase of accelerated growth.

• XOMA Declares Quarterly Preferred Stock Dividends - December 22, 2022

  12/22/2022

  XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by Organon

  11/22/2022

  XOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay.

• XOMA Reports Third Quarter 2022 Financial Results and Highlights Recent Operational Events

  11/3/2022

  XOMA Corporation (Nasdaq: XOMA), a biotech royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of advancing novel therapeutic candidates aimed at improving human health, reported its third quarter 2022 financial results and provided a recent operations update.

• XOMA Declares Quarterly Preferred Stock Dividends - September 21, 2022

  9/21/2022

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at H.C. Wainwright 24th Annual Global Investment Conference

  9/7/2022

  XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022, at 10:00 AM ET.

• XOMA Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Events

  8/4/2022

  XOMA Corporation reported its second quarter 2022 financial results and provided a recent operations update.

• XOMA Declares Quarterly Preferred Stock Dividends - June 20, 2022

  6/20/2022

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at H.C. Wainwright Global Investment Conference

  5/17/2022

  XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 10:00 AM ET.

• XOMA Reports First Quarter 2022 Financial Results and Highlights Recent Operational Events

  5/5/2022

  XOMA Corporation reported its first quarter 2022 financial results and provided a recent operations update.

• XOMA Declares Quarterly Preferred Stock Dividends - Mar 21, 2022

  3/21/2022

  XOMA Corporation announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock.

• XOMA to Present at Oppenheimer’s 32nd Annual Healthcare Conference

  3/10/2022

  XOMA Corporation announced today its Chairman and Chief Executive Officer, Jim Neal, will present at Oppenheimer’s 32nd Annual Healthcare Conference (virtual) on Thursday, March 17, 2022, at 12:40 PM ET.

• XOMA Reports Full Year 2021 Financial Results and Highlights Recent Operational Events

  3/8/2022

  XOMA Corporation, a biotech royalty aggregator playing a distinctive role in helping companies achieve their goal of improving human health, reported its 2021 financial results and provided a recent operations update.

• XOMA to Present at the 42nd Annual Cowen Health Care Conference

  3/1/2022

  XOMA Corporation announced its Chairman and Chief Executive Officer, Jim Neal, will be featured in a fireside chat at the 42nd Annual Cowen Health Care Conference on Monday, March 7, 2022, at 1:30 PM ET.

• XOMA to Present at Aegis Capital Corp Investor Conference

  2/17/2022

  XOMA Corporation announced today its Chief Executive Officer, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET. 

• 

  Predicting the Life Sciences Investment Market in 2022

  1/6/2022

  Mark Charest, Ph.D., of LifeSci Fund Management, said the J.P. Morgan Healthcare Conference will set the tone for biotech stock performance in 1H 2022.